Basal Tumours in Bladder Cancer, Response to chemoTherapy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Bladder Cancer
- Sponsor
- University Hospital, Rouen
- Enrollment
- 293
- Locations
- 1
- Primary Endpoint
- Identifying mechanisms of resistance in basal subgroups.
- Status
- Completed
- Last Updated
- 11 months ago
Overview
Brief Summary
Determine the sensitivity/resistance to chemotherapy of the various subgroups of muscle-invasive bladder cancers, including the basal subgroup (about 25% of these tumours) according to 4 different classifications based on molecular or immunohistochemical classifiers.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients enrolled in VESPER study:Tumors from patient having withdrawn his/her informed consent form for the participation to the collection and/or VESPER project.
- •Patients from St Louis not enrolled in VESPER study:Tumors from patient having expressed opposition against research program after 1 month for the participation to the collection.
Outcomes
Primary Outcomes
Identifying mechanisms of resistance in basal subgroups.
Time Frame: through study completion, an average of 3 years
Identifying molecular subgroups of bladder cancer patients within VESPER and Saint-Louis cohort, who could benefit from neoadjuvant chemotherapy, taking into account the existence of different classification systems.
Time Frame: through study completion, an average of 3 years
Determining which classification(s) has(ve) the best ability to identifying subgroups of tumours sensitive or resistant to neoadjuvant chemotherapy.
Time Frame: through study completion, an average of 3 years